Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors

Những quyển sách tương tự

• Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus
  Bằng: Piha-Paul, Sarina A., et al.
  Được phát hành: (2014)
• Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus
  Bằng: Liu, Xiaochun, et al.
  Được phát hành: (2016)
• PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
  Bằng: Janku, Filip, et al.
  Được phát hành: (2011)
• PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early phase clinical trials
  Bằng: Janku, Filip, et al.
  Được phát hành: (2012)
• Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing’s Sarcoma Family Tumors
  Bằng: Naing, Aung, et al.
  Được phát hành: (2012)